263 related articles for article (PubMed ID: 7528120)
1. [Sharing antigenic determinant of colon carcinoma between serous and mucinous tumors of the ovary].
Liu MP; Lu ZT; Chen W
Zhonghua Fu Chan Ke Za Zhi; 1994 Jul; 29(7):398-400, 444. PubMed ID: 7528120
[TBL] [Abstract][Full Text] [Related]
2. Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts.
Yang JM; Southern JF; Warshaw AL; Lewandrowski KB
Am J Surg; 1996 Jan; 171(1):126-9; discussion 129-30. PubMed ID: 8554126
[TBL] [Abstract][Full Text] [Related]
3. Identification of two different surface epitopes of human ovarian epithelial carcinomas by monoclonal antibodies.
Tsuji Y; Suzuki T; Nishiura H; Takemura T; Isojima S
Cancer Res; 1985 May; 45(5):2358-62. PubMed ID: 2580620
[TBL] [Abstract][Full Text] [Related]
4. [Distribution and diagnostic role of COTA in mucinous ovarian tumors].
Shi ZL
Zhonghua Zhong Liu Za Zhi; 1989 May; 11(3):191-2. PubMed ID: 2612330
[TBL] [Abstract][Full Text] [Related]
5. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
6. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors.
Choi YL; Kim SH; Shin YK; Hong YC; Lee SJ; Kang SY; Ahn G
Gynecol Oncol; 2005 May; 97(2):379-86. PubMed ID: 15863133
[TBL] [Abstract][Full Text] [Related]
7. Three novel mouse monoclonal antibodies, OM-A, OM-B, and OM-C, reactive with mucinous type ovarian tumors.
Sakakibara K; Ueda R; Ohta M; Nakashima N; Tomoda Y; Takahashi T
Cancer Res; 1988 Aug; 48(16):4639-45. PubMed ID: 2456145
[TBL] [Abstract][Full Text] [Related]
8. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.
Wen YH; Yee H; Goswami S; Shukla PS
Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814
[TBL] [Abstract][Full Text] [Related]
9. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
Yakirevich E; Sabo E; Lavie O; Mazareb S; Spagnoli GC; Resnick MB
Clin Cancer Res; 2003 Dec; 9(17):6453-60. PubMed ID: 14695148
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies recognizing tumor-associated antigen of human ovarian mucinous cystadenocarcinomas.
Bhattacharya M; Chatterjee SK; Barlow JJ; Fuji H
Cancer Res; 1982 May; 42(5):1650-4. PubMed ID: 6175395
[TBL] [Abstract][Full Text] [Related]
11. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
[TBL] [Abstract][Full Text] [Related]
12. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
Esheba GE; Pate LL; Longacre TA
Am J Surg Pathol; 2008 Apr; 32(4):600-7. PubMed ID: 18277882
[TBL] [Abstract][Full Text] [Related]
13. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
15. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
[TBL] [Abstract][Full Text] [Related]
17. [Serological analysis of antibodies by anti-idiotypic monoclonal antibody 6B11 against ovarian carcinoma].
Feng J; Lü J; Qian H
Zhonghua Fu Chan Ke Za Zhi; 1996 Aug; 31(8):493-5. PubMed ID: 9275445
[TBL] [Abstract][Full Text] [Related]
18. Differentiation margins of ovarian tumor pathology: first incidences of epithelial ovarian tumors monitored by marker antibodies.
van Niekerk CC; Vooijs P; Casparie-van Velsen IJ; Poels LG
Cancer Detect Prev; 1997; 21(3):247-57. PubMed ID: 9167042
[TBL] [Abstract][Full Text] [Related]
19. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer.
Zheng W; Luo MP; Welt C; Lambert-Messerlian G; Sung CJ; Zhang Z; Ying SY; Schneyer AL; Lauchlan SC; Felix JC
Gynecol Oncol; 1998 Apr; 69(1):23-31. PubMed ID: 9570994
[TBL] [Abstract][Full Text] [Related]
20. Changes in expression of differentiation markers between normal ovarian cells and derived tumors.
Van Niekerk CC; Ramaekers FC; Hanselaar AG; Aldeweireldt J; Poels LG
Am J Pathol; 1993 Jan; 142(1):157-77. PubMed ID: 7678716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
